Chief Judge Michael Shea delivered a sharp blow to attorneys general from 45 states on Tuesday. In a Connecticut federal courtroom, he tossed Pfizer from a sprawling antitrust case accusing the drugmaker and dozens of others of rigging prices on generic medicines. The ruling centers on activity from 2010 to 2014 involving Pfizer’s former Greenstone unit.
States had pointed to more than 360 phone calls and texts between Greenstone executives and counterparts at Sandoz. They claimed coordination on bids and customer allocation for six products. These included generic eplerenone tablets to treat high blood pressure, latanoprost eye drops for glaucoma, and four formulations of clindamycin phosphate used against acne.
But Shea saw insufficient evidence. “Greenstone existed for the purpose of selling generic drugs for profit in addition to the strategic value that it provided to its parent company,” he wrote. “The states’ contention that it existed for the sole purpose of acting on its parent company’s behalf falls short.” No reasonable jury could find direct conspiracy by Pfizer. Or knowledge of collusion when approving price changes. Or liability through an agency relationship with Greenstone.
Legal setbacks mount for states in long-running generic drug probes
The decision marks one early victory for industry defendants in litigation that once looked ominous. The suit, led by Connecticut Attorney General William Tong, targeted 36 companies over pricing on 80 generic drugs. Most treated common skin conditions. New York Attorney General Letitia James filed briefs opposing Pfizer’s push for dismissal. Neither office offered immediate comment Wednesday.
Pfizer spun off Greenstone in 2020. The transaction created Viatris. Company officials expressed satisfaction with the outcome. “Greenstone was a reliable and trusted supplier of affordable generic medicines for decades, and we will continue to vigorously defend against these claims,” Pfizer said in a statement, according to Yahoo Finance.
Shea continues to oversee two other antitrust suits brought by state attorneys general over generic drugs. Pfizer remains a defendant in one of them. The broader cases stem from years of federal and state investigations into generic pharmaceutical pricing practices. Prosecutors and civil enforcers have extracted billions in settlements from multiple manufacturers over the past decade.
This dismissal arrives against a backdrop of persistent pressure on drug costs. Federal lawmakers, state officials and patient advocates continue to scrutinize how prices reach patients. Recent developments show the tension. In September 2025, Pfizer announced a landmark voluntary agreement with the Trump administration to align U.S. prices more closely with those in other developed countries for certain medicines. The deal aimed to head off potential tariffs while encouraging domestic manufacturing investment, Pfizer’s own press release detailed.
Yet other fronts remain active. Pharmaceutical companies have faced repeated courtroom defeats in challenges to the Inflation Reduction Act’s Medicare drug price negotiation program. The U.S. Supreme Court in May 2026 rebuffed several such efforts. Lower courts had already rejected constitutional and statutory arguments from manufacturers including Novartis, AstraZeneca and others. A Harvard Petrie-Flom Center analysis in February 2026 cataloged a string of 10 district court losses and six circuit court defeats for pharma on the merits.
But antitrust claims over historical generic pricing follow a different path. Here, evidence of communications between sales teams often drives the disputes. States alleged Greenstone and Sandoz swapped information to stabilize markets and avoid price erosion. Typical in the generics business, where thin margins and commoditized products create strong incentives for coordination.
Judge Shea’s opinion underscores a key hurdle for plaintiffs. Proving parent company liability for actions of a subsidiary demands more than shared ownership or occasional oversight. Greenstone operated with its own profit motive. Strategic benefits to Pfizer existed. Yet that alone did not transform routine business decisions into evidence of conspiracy.
Market reaction appeared muted but positive. Social media commentary on X highlighted relief for the company’s stock. One trader noted the removal of “a substantial cloud” after recent negative headlines involving executive departures and clinical trial results. Another called it a “balance sheet re-rating event.” Such legal wins rarely move share prices dramatically. They do reduce uncertainty for investors and management alike.
The case offers lessons for how these sprawling multidistrict litigations unfold. Attorneys general often file sweeping complaints. They name many defendants and products. Discovery then reveals which claims hold water. Many cases settle. Some get pared back through motions practice, as happened here. Pfizer’s success may encourage similar arguments from remaining defendants.
Critics of the industry see a pattern. Drugmakers enjoy patent protection on innovative products. Then generics enter at lower prices. But if manufacturers collude to blunt that competition, patients and payers lose. States have recovered hundreds of millions in past settlements over similar allegations involving other companies and drugs.
Pfizer itself has settled related pricing matters before. In 2021 it agreed to pay $345 million to resolve claims tied to EpiPen pricing practices. Mylan, the primary defendant in those suits, faced even larger penalties. Those cases involved different theories. They focused on marketing tactics, patent strategies and rebate structures rather than direct generic price fixing. Still, they contributed to a narrative of aggressive pricing across the sector.
Industry defenders counter that generics have dramatically lowered costs for Americans over decades. Pfizer noted Greenstone’s role supplying affordable versions of medicines for years. The spin-off to Viatris continued that mission under new ownership. Legal outcomes like Tuesday’s ruling reinforce that not every allegation survives scrutiny.
What’s next? The litigation against other defendants proceeds. Shea will manage the docket. States might appeal the Pfizer dismissal, though success appears uncertain given the opinion’s clarity. Broader policy debates over drug costs show no signs of fading. Congress, the executive branch and regulators keep testing new approaches. From voluntary international price alignment to Medicare negotiation, the pressure continues.
For Pfizer, the immediate effect is straightforward. One significant legal risk disappears. Resources once devoted to defense can shift elsewhere. And the precedent may help other companies facing parallel claims. The decision won’t quiet calls for lower prices. It does illustrate that courts still require concrete proof before imposing liability in complex antitrust disputes.
That distinction matters. Communications between competitors invite suspicion. Yet ordinary business activity within a corporate family does not automatically equal conspiracy. Judge Shea drew that line. Other judges in similar cases will study exactly where he placed it.
WebProNews is an iEntry Publication